8 results about "Nuclear translocation" patented technology

This invention discloses the application and method of a STAT1-targeting inhibitor in the treatment of immune thrombocytopenic purpura (ITP). It employs ivermectin, a STAT1 nuclear translocation inhibitor, and fludarabine, a STAT1 activation inhibitor. By injecting either the activation inhibitor or the nuclear translocation inhibitor, the platelet count in a mouse model of ITP is increased. Fludarabine, a fluorinated nucleotide analog of vidarabine, is non-radioactive and a small-molecule phosphorylation inhibitor. Ivermectin is a small-molecule inhibitor of nuclear translocation mediated by α / β1 introgression protein. Both have high bioavailability and are widely used to treat various hematological diseases with good safety profiles. Their application in treating ITP is safe, effective, and shows high compliance.

This invention proposes the application of psoralen as an Nrf2 agonist in drug preparation. This invention is the first to discover that psoralen is a specific Nrf2 agonist. Psoralen can directly target and bind to the Nrf2 protein, improving its stability, promoting its phosphorylation and nuclear translocation, thereby activating the Nrf2 signaling pathway, upregulating the expression of downstream antioxidant, anti-inflammatory, and anti-ferroptosis-related proteins, and achieving cell protection and tissue repair functions.

The application belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of umbilical cord blood plasma-derived extracellular vesicles and related bioactive molecules thereof in treatment of Alzheimer's disease. Specifically, the application isolates extracellular vesicles (UCBP-sEVs) from umbilical cord blood plasma, which has the effect of improving Alzheimer's disease. Further research finds that high enrichment of miR-16-2-3p therein is a key molecule for mediating treatment of Alzheimer's disease. miR-16-2-3p targets and inhibits expression of ROCK2, reduces phosphorylation level of TFEB and promotes nuclear translocation of the same, activates microglial autophagy-lysosome pathway, and thus promotes phagocytosis and degradation of intracerebral beta amyloid, and therefore has good practical application value.

This invention relates to the field of biomedical technology, and more particularly to the application of an isoflavone compound, specifically Corylifol A, in the preparation of drugs for the prevention and / or treatment of inflammatory diseases. When used to prepare drugs for the prevention and / or treatment of inflammatory diseases, this isoflavone compound can directly bind to the IκBα protein and specifically inhibit its phosphorylation, thereby blocking the phosphorylation and nuclear translocation of the NF-κB p65 subunit, ultimately inhibiting the overactivation of the NF-κB signaling pathway. Furthermore, the isoflavone compound can significantly reduce the mortality rate of lipopolysaccharide-induced septicemia in mice, inhibit the levels of inflammatory factors in serum and lung tissue, and effectively alleviate LPS-induced acute lung injury in mice. Simultaneously, when the isoflavone compound is controlled within an effective concentration range, it exhibits no significant cytotoxicity to mouse peritoneal macrophages and can significantly inhibit the production and release of lipopolysaccharide-induced inflammatory factors IL-1β, TNF-α, and IL-6.

This invention provides the application of the LHPP gene in liver cancer immunotherapy and liver cancer immunotherapy drugs. Reagents that promote LHPP gene expression can be used to prepare liver cancer immunotherapy drugs. This invention also provides an mRNA nanomedicine, which is prepared by the following method: [The invention then describes a process involving Meo-PEG-Dlink]. m A PLGA solution, an aqueous solution of LHPP gene mRNA, and a cationic liposome solution were mixed and added dropwise to water under stirring to obtain a nanosolution. The nanosolution was then transferred to an ultrafiltration membrane and centrifuged. This invention is the first to discover that LHPP can participate in the immunotherapy of liver cancer and is associated with the survival prognosis of liver cancer. LHPP enhances STAT1 nuclear translocation by affecting the expression of autophagy-regulated IFNβ, thereby promoting the expression of T cell-related chemokines secreted by liver cancer cells, and ultimately promoting CD8+ expression. + T cell infiltration. Therefore, the LHPP gene can serve as a novel target for immunotherapy of liver cancer. The mRNA nanomedicine described has advantages such as long circulation time in the blood, high accumulation in tumors, rapid mRNA release, and low cost.

The application discloses application of a polypeptide in preparation of a drug for treating or relieving PTSD. The application first discovers a specific scaffold protein FRMD5 of a protein isoform, the protein isoform can form a nuclear condensate, is combined with a group of unique protein partners (rich in GR chaperone cycle components and transcriptional co-regulators), and can reshape nuclear translocation, transcriptional activity and target gene expression of GR. An interfering peptide is designed aiming at the target, can regulate the nuclear translocation, transcriptional activity and target gene expression of GR, and can relieve stress response of a mouse. The application can be applied to preparation of a drug for treating or relieving PTSD.

The application discloses application of a compound for inhibiting HIBCH nuclear translocation in preparation of a medicine for reversing resistance of a breast cancer PI3K alpha inhibitor, and relates to the technical field of biological medicines.It is found by the application that valine metabolism is disordered in a breast cancer cell and an animal model resistant to a PI3K alpha inhibitor, and the valine metabolism disorder is caused by translocation of a key enzyme HIBCH of a valine degradation pathway originally positioned in mitochondria to a cell nucleus.Targeting HIBCH and combining the PI3K alpha inhibitor have a synergistic lethal effect on breast cancer, can significantly enhance sensitivity of tumor cells to the PI3K alpha inhibitor, and the treatment effect is not affected by whether PIK3CA itself is mutated or not.The treatment strategy of targeting HIBCH and combining the PI3K alpha inhibitor not only enhances the treatment effect of the PI3K alpha inhibitor, but also expands an adaptability population of the PI3K alpha inhibitor in breast cancer treatment.

The present application relates to the technical field of pharmaceutical chemistry, and discloses a kind of guaiane type sesquiterpene lactone compound, wild chrysanthemum extract and its preparation method and application.The guaiane type sesquiterpene lactone compound has the structure shown in formula (I).Research shows that the guaiane type sesquiterpene lactone compound with the structure shown in formula (I) and wild chrysanthemum extract have obvious inhibitory effect on NF-κB nuclear translocation.Therefore, further using the guaiane type sesquiterpene lactone compound with the structure shown in formula (I) or wild chrysanthemum extract as effective component for preparing anti-inflammatory drugs and treating inflammatory diseases caused by NF-κB nuclear translocation has important application value.